Global Bio-pharmaceuticals Market
Global Bio-pharmaceuticals Market

Bio-pharmaceuticals Comprehensive Study by Type (Monoclonal Antibodies (moAb), Biotech Vaccines, Recombinant Human (RH) Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH), Other Biopharmaceuticals), Application (Oncology, Autoimmune Disorders, Diabetes, Inflammatory and Infectious Diseases, Neurological Diseases, Cardiovascular Diseases, Others), End Users (Pharmaceutical companies, Biopharmaceutical companies, Hospitals and clinics, Research and development centers, Clinical trial centers), Technology (Genome-based technologies, Gene therapy, Software, Artificial Intelligence), Sales Channel (Prescription, OTC) Players and Region - Global Market Outlook to 2024

Bio-pharmaceuticals Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Mar 2020 Edition 225 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Bio-pharmaceuticals Market Overview:
Basically, Bio-pharmaceuticals are categorized under the pharmaceutical industry. The combination of biological applications with pharmaceutical enhancements the new department of Bio-Pharma introduced. Bio-pharmaceuticals drugs and therapies are therapeutic agents initialized to treat symptoms and/or underlying causes of a variety of disorders and diseases. Commonly, it is also known as bio-pharmaceutical. It opens doors for various medications for untreated diseases and disorders with very few side effects. Some of the key players profiled in the study are Pfizer (United States), F. Hoffmann-La Roche AG, AbbVie(United States), Johnson& Johnson (United States), Sanofi (France), AstraZeneca (United Kingdom), Novartis (Switzerland), Novo Nordisk (Denmark), Merck & Co., Inc. (United States), Eli Lilly and Company (United States), Bristol-Myers Squibb Company (United States), Cadila Healthcare Limited (Zydus Cadila) (India), Amgen (United States), Abbott Laboratories (United States) and Biocon Ltd (India).

On the basis of geography, the market of Bio-pharmaceuticals has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Pharmaceutical companies will boost the Bio-pharmaceuticals market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Technology, the sub-segment i.e. Genome-based technologies will boost the Bio-pharmaceuticals market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sales Channel, the sub-segment i.e. Prescription will boost the Bio-pharmaceuticals market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Elderly Population
  • Biopharmaceuticals Provide Several Advantages As They Are Highly Effective And Potent In Action With Only A Few Side Effects

Market Trend
  • Highly Demanded as Alternative For Many Traditional Medications

Restraints
  • High Cost Associated With The Production, Research, And All Requirements

Opportunities
  • Occurrence E Of Chronic Diseases Like Cancer, HIV/AIDS And Diabetes, Etc
  • Growing Acceptance And Adoption Of Biopharmaceuticals Due Effectiveness In Untreatable Diseases

Challenges
  • Research Studies Take A Long Time Period Getting Desirable Results
  • Stringent Regulatory Guidelines


Major Market Developments:

On 13th January 2020, Amgen announced a diagnostic merger with leading diagnostic Guardant Health and it will develop Blood- and Tissue-Based Companion Diagnostics for Investigational KRAS to expand molecular testing for patients. It will be the first company developing a KRAS inhibitor in multi diagnostic.
On 25th February FDA accepted Roche’s Biologics license application for fixed-dose via subcutaneous combination Perjeta and Herceptin for HER2-positive breast cancer. It will facilitate chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.

The top firms are in a competition that has their strong R&D backup for research studies and the further things which are required to get approval for such complicated drugs and enhance the treatment medications. There are firms mainly from the USA and playing a major role in the research area of Biopharmaceuticals. The mergers and acquisitions are other options to change the market strategies and earn more reputation in the market.

Target Audience:
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Clinical Trial Centres and Downstream Vendors

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Bio-pharmaceuticals market on the basis of product [Monoclonal Antibodies (moAb), Biotech Vaccines, Recombinant Human (RH) Insulin, Erythropoietin, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Human Growth Hormones (HGH) and Other Biopharmaceuticals] , application [Oncology, Autoimmune Disorders, Diabetes, Inflammatory and Infectious Diseases, Neurological Diseases, Cardiovascular Diseases and Others], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Bio-pharmaceuticals market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Bio-pharmaceuticals industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Bio-pharmaceuticals market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Monoclonal Antibodies (moAb)
  • Biotech Vaccines
  • Recombinant Human (RH) Insulin
  • Erythropoietin
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Interferons
  • Human Growth Hormones (HGH)
  • Other Biopharmaceuticals
By Application
  • Oncology
  • Autoimmune Disorders
  • Diabetes
  • Inflammatory and Infectious Diseases
  • Neurological Diseases
  • Cardiovascular Diseases
  • Others
By End Users
  • Pharmaceutical companies
  • Biopharmaceutical companies
  • Hospitals and clinics
  • Research and development centers
  • Clinical trial centers

By Technology
  • Genome-based technologies
  • Gene therapy
  • Software
  • Artificial Intelligence

By Sales Channel
  • Prescription
  • OTC

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Elderly Population
      • 3.2.2. Biopharmaceuticals Provide Several Advantages As They Are Highly Effective And Potent In Action With Only A Few Side Effects
    • 3.3. Market Challenges
      • 3.3.1. Research Studies Take A Long Time Period Getting Desirable Results
      • 3.3.2. Stringent Regulatory Guidelines
    • 3.4. Market Trends
      • 3.4.1. Highly Demanded as Alternative For Many Traditional Medications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bio-pharmaceuticals, by Type, Application, End Users, Technology, Sales Channel and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Bio-pharmaceuticals (Value)
      • 5.2.1. Global Bio-pharmaceuticals by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies (moAb)
        • 5.2.1.2. Biotech Vaccines
        • 5.2.1.3. Recombinant Human (RH) Insulin
        • 5.2.1.4. Erythropoietin
        • 5.2.1.5. Granulocyte Colony-Stimulating Factor (G-CSF)
        • 5.2.1.6. Interferons
        • 5.2.1.7. Human Growth Hormones (HGH)
        • 5.2.1.8. Other Biopharmaceuticals
      • 5.2.2. Global Bio-pharmaceuticals by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Autoimmune Disorders
        • 5.2.2.3. Diabetes
        • 5.2.2.4. Inflammatory and Infectious Diseases
        • 5.2.2.5. Neurological Diseases
        • 5.2.2.6. Cardiovascular Diseases
        • 5.2.2.7. Others
      • 5.2.3. Global Bio-pharmaceuticals by: End Users (Value)
        • 5.2.3.1. Pharmaceutical companies
        • 5.2.3.2. Biopharmaceutical companies
        • 5.2.3.3. Hospitals and clinics
        • 5.2.3.4. Research and development centers
        • 5.2.3.5. Clinical trial centers
      • 5.2.4. Global Bio-pharmaceuticals by: Technology (Value)
        • 5.2.4.1. Genome-based technologies
        • 5.2.4.2. Gene therapy
        • 5.2.4.3. Software
        • 5.2.4.4. Artificial Intelligence
      • 5.2.5. Global Bio-pharmaceuticals by: Sales Channel (Value)
        • 5.2.5.1. Prescription
        • 5.2.5.2. OTC
      • 5.2.6. Global Bio-pharmaceuticals Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Bio-pharmaceuticals: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche AG
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson& Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novo Nordisk (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co., Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eli Lilly and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Bristol-Myers Squibb Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Cadila Healthcare Limited (Zydus Cadila) (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Amgen (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Abbott Laboratories (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Biocon Ltd (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Bio-pharmaceuticals Sale, by Type, Application, End Users, Technology, Sales Channel and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Bio-pharmaceuticals (Value)
      • 7.2.1. Global Bio-pharmaceuticals by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies (moAb)
        • 7.2.1.2. Biotech Vaccines
        • 7.2.1.3. Recombinant Human (RH) Insulin
        • 7.2.1.4. Erythropoietin
        • 7.2.1.5. Granulocyte Colony-Stimulating Factor (G-CSF)
        • 7.2.1.6. Interferons
        • 7.2.1.7. Human Growth Hormones (HGH)
        • 7.2.1.8. Other Biopharmaceuticals
      • 7.2.2. Global Bio-pharmaceuticals by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Autoimmune Disorders
        • 7.2.2.3. Diabetes
        • 7.2.2.4. Inflammatory and Infectious Diseases
        • 7.2.2.5. Neurological Diseases
        • 7.2.2.6. Cardiovascular Diseases
        • 7.2.2.7. Others
      • 7.2.3. Global Bio-pharmaceuticals by: End Users (Value)
        • 7.2.3.1. Pharmaceutical companies
        • 7.2.3.2. Biopharmaceutical companies
        • 7.2.3.3. Hospitals and clinics
        • 7.2.3.4. Research and development centers
        • 7.2.3.5. Clinical trial centers
      • 7.2.4. Global Bio-pharmaceuticals by: Technology (Value)
        • 7.2.4.1. Genome-based technologies
        • 7.2.4.2. Gene therapy
        • 7.2.4.3. Software
        • 7.2.4.4. Artificial Intelligence
      • 7.2.5. Global Bio-pharmaceuticals by: Sales Channel (Value)
        • 7.2.5.1. Prescription
        • 7.2.5.2. OTC
      • 7.2.6. Global Bio-pharmaceuticals Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bio-pharmaceuticals: by Type(USD Million)
  • Table 2. Bio-pharmaceuticals Monoclonal Antibodies (moAb) , by Region USD Million (2013-2018)
  • Table 3. Bio-pharmaceuticals Biotech Vaccines , by Region USD Million (2013-2018)
  • Table 4. Bio-pharmaceuticals Recombinant Human (RH) Insulin , by Region USD Million (2013-2018)
  • Table 5. Bio-pharmaceuticals Erythropoietin , by Region USD Million (2013-2018)
  • Table 6. Bio-pharmaceuticals Granulocyte Colony-Stimulating Factor (G-CSF) , by Region USD Million (2013-2018)
  • Table 7. Bio-pharmaceuticals Interferons , by Region USD Million (2013-2018)
  • Table 8. Bio-pharmaceuticals Human Growth Hormones (HGH) , by Region USD Million (2013-2018)
  • Table 9. Bio-pharmaceuticals Other Biopharmaceuticals , by Region USD Million (2013-2018)
  • Table 10. Bio-pharmaceuticals: by Application(USD Million)
  • Table 11. Bio-pharmaceuticals Oncology , by Region USD Million (2013-2018)
  • Table 12. Bio-pharmaceuticals Autoimmune Disorders , by Region USD Million (2013-2018)
  • Table 13. Bio-pharmaceuticals Diabetes , by Region USD Million (2013-2018)
  • Table 14. Bio-pharmaceuticals Inflammatory and Infectious Diseases , by Region USD Million (2013-2018)
  • Table 15. Bio-pharmaceuticals Neurological Diseases , by Region USD Million (2013-2018)
  • Table 16. Bio-pharmaceuticals Cardiovascular Diseases , by Region USD Million (2013-2018)
  • Table 17. Bio-pharmaceuticals Others , by Region USD Million (2013-2018)
  • Table 18. Bio-pharmaceuticals: by End Users(USD Million)
  • Table 19. Bio-pharmaceuticals Pharmaceutical companies , by Region USD Million (2013-2018)
  • Table 20. Bio-pharmaceuticals Biopharmaceutical companies , by Region USD Million (2013-2018)
  • Table 21. Bio-pharmaceuticals Hospitals and clinics , by Region USD Million (2013-2018)
  • Table 22. Bio-pharmaceuticals Research and development centers , by Region USD Million (2013-2018)
  • Table 23. Bio-pharmaceuticals Clinical trial centers , by Region USD Million (2013-2018)
  • Table 24. Bio-pharmaceuticals: by Technology(USD Million)
  • Table 25. Bio-pharmaceuticals Genome-based technologies , by Region USD Million (2013-2018)
  • Table 26. Bio-pharmaceuticals Gene therapy , by Region USD Million (2013-2018)
  • Table 27. Bio-pharmaceuticals Software , by Region USD Million (2013-2018)
  • Table 28. Bio-pharmaceuticals Artificial Intelligence , by Region USD Million (2013-2018)
  • Table 29. Bio-pharmaceuticals: by Sales Channel(USD Million)
  • Table 30. Bio-pharmaceuticals Prescription , by Region USD Million (2013-2018)
  • Table 31. Bio-pharmaceuticals OTC , by Region USD Million (2013-2018)
  • Table 32. South America Bio-pharmaceuticals, by Country USD Million (2013-2018)
  • Table 33. South America Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 34. South America Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 35. South America Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 36. South America Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 37. South America Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 38. Brazil Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 39. Brazil Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 40. Brazil Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 41. Brazil Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 42. Brazil Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 43. Argentina Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 44. Argentina Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 45. Argentina Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 46. Argentina Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 47. Argentina Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 48. Rest of South America Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 49. Rest of South America Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 50. Rest of South America Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 51. Rest of South America Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 52. Rest of South America Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 53. Asia Pacific Bio-pharmaceuticals, by Country USD Million (2013-2018)
  • Table 54. Asia Pacific Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 55. Asia Pacific Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 56. Asia Pacific Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 57. Asia Pacific Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 58. Asia Pacific Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 59. China Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 60. China Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 61. China Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 62. China Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 63. China Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 64. Japan Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 65. Japan Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 66. Japan Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 67. Japan Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 68. Japan Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 69. India Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 70. India Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 71. India Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 72. India Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 73. India Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 74. South Korea Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 75. South Korea Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 76. South Korea Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 77. South Korea Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 78. South Korea Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 79. Taiwan Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 80. Taiwan Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 81. Taiwan Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 82. Taiwan Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 83. Taiwan Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 84. Australia Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 85. Australia Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 86. Australia Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 87. Australia Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 88. Australia Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 89. Rest of Asia-Pacific Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 90. Rest of Asia-Pacific Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 91. Rest of Asia-Pacific Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 92. Rest of Asia-Pacific Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 93. Rest of Asia-Pacific Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 94. Europe Bio-pharmaceuticals, by Country USD Million (2013-2018)
  • Table 95. Europe Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 96. Europe Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 97. Europe Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 98. Europe Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 99. Europe Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 100. Germany Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 101. Germany Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 102. Germany Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 103. Germany Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 104. Germany Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 105. France Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 106. France Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 107. France Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 108. France Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 109. France Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 110. Italy Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 111. Italy Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 112. Italy Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 113. Italy Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 114. Italy Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 115. United Kingdom Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 116. United Kingdom Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 117. United Kingdom Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 118. United Kingdom Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 119. United Kingdom Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 120. Netherlands Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 121. Netherlands Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 122. Netherlands Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 123. Netherlands Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 124. Netherlands Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 125. Rest of Europe Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 126. Rest of Europe Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 127. Rest of Europe Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 128. Rest of Europe Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 129. Rest of Europe Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 130. MEA Bio-pharmaceuticals, by Country USD Million (2013-2018)
  • Table 131. MEA Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 132. MEA Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 133. MEA Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 134. MEA Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 135. MEA Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 136. Middle East Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 137. Middle East Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 138. Middle East Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 139. Middle East Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 140. Middle East Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 141. Africa Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 142. Africa Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 143. Africa Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 144. Africa Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 145. Africa Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 146. North America Bio-pharmaceuticals, by Country USD Million (2013-2018)
  • Table 147. North America Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 148. North America Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 149. North America Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 150. North America Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 151. North America Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 152. United States Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 153. United States Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 154. United States Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 155. United States Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 156. United States Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 157. Canada Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 158. Canada Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 159. Canada Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 160. Canada Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 161. Canada Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 162. Mexico Bio-pharmaceuticals, by Type USD Million (2013-2018)
  • Table 163. Mexico Bio-pharmaceuticals, by Application USD Million (2013-2018)
  • Table 164. Mexico Bio-pharmaceuticals, by End Users USD Million (2013-2018)
  • Table 165. Mexico Bio-pharmaceuticals, by Technology USD Million (2013-2018)
  • Table 166. Mexico Bio-pharmaceuticals, by Sales Channel USD Million (2013-2018)
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Bio-pharmaceuticals: by Type(USD Million)
  • Table 183. Bio-pharmaceuticals Monoclonal Antibodies (moAb) , by Region USD Million (2019-2024)
  • Table 184. Bio-pharmaceuticals Biotech Vaccines , by Region USD Million (2019-2024)
  • Table 185. Bio-pharmaceuticals Recombinant Human (RH) Insulin , by Region USD Million (2019-2024)
  • Table 186. Bio-pharmaceuticals Erythropoietin , by Region USD Million (2019-2024)
  • Table 187. Bio-pharmaceuticals Granulocyte Colony-Stimulating Factor (G-CSF) , by Region USD Million (2019-2024)
  • Table 188. Bio-pharmaceuticals Interferons , by Region USD Million (2019-2024)
  • Table 189. Bio-pharmaceuticals Human Growth Hormones (HGH) , by Region USD Million (2019-2024)
  • Table 190. Bio-pharmaceuticals Other Biopharmaceuticals , by Region USD Million (2019-2024)
  • Table 191. Bio-pharmaceuticals: by Application(USD Million)
  • Table 192. Bio-pharmaceuticals Oncology , by Region USD Million (2019-2024)
  • Table 193. Bio-pharmaceuticals Autoimmune Disorders , by Region USD Million (2019-2024)
  • Table 194. Bio-pharmaceuticals Diabetes , by Region USD Million (2019-2024)
  • Table 195. Bio-pharmaceuticals Inflammatory and Infectious Diseases , by Region USD Million (2019-2024)
  • Table 196. Bio-pharmaceuticals Neurological Diseases , by Region USD Million (2019-2024)
  • Table 197. Bio-pharmaceuticals Cardiovascular Diseases , by Region USD Million (2019-2024)
  • Table 198. Bio-pharmaceuticals Others , by Region USD Million (2019-2024)
  • Table 199. Bio-pharmaceuticals: by End Users(USD Million)
  • Table 200. Bio-pharmaceuticals Pharmaceutical companies , by Region USD Million (2019-2024)
  • Table 201. Bio-pharmaceuticals Biopharmaceutical companies , by Region USD Million (2019-2024)
  • Table 202. Bio-pharmaceuticals Hospitals and clinics , by Region USD Million (2019-2024)
  • Table 203. Bio-pharmaceuticals Research and development centers , by Region USD Million (2019-2024)
  • Table 204. Bio-pharmaceuticals Clinical trial centers , by Region USD Million (2019-2024)
  • Table 205. Bio-pharmaceuticals: by Technology(USD Million)
  • Table 206. Bio-pharmaceuticals Genome-based technologies , by Region USD Million (2019-2024)
  • Table 207. Bio-pharmaceuticals Gene therapy , by Region USD Million (2019-2024)
  • Table 208. Bio-pharmaceuticals Software , by Region USD Million (2019-2024)
  • Table 209. Bio-pharmaceuticals Artificial Intelligence , by Region USD Million (2019-2024)
  • Table 210. Bio-pharmaceuticals: by Sales Channel(USD Million)
  • Table 211. Bio-pharmaceuticals Prescription , by Region USD Million (2019-2024)
  • Table 212. Bio-pharmaceuticals OTC , by Region USD Million (2019-2024)
  • Table 213. South America Bio-pharmaceuticals, by Country USD Million (2019-2024)
  • Table 214. South America Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 215. South America Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 216. South America Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 217. South America Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 218. South America Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 219. Brazil Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 220. Brazil Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 221. Brazil Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 222. Brazil Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 223. Brazil Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 224. Argentina Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 225. Argentina Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 226. Argentina Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 227. Argentina Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 228. Argentina Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 229. Rest of South America Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 230. Rest of South America Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 231. Rest of South America Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 232. Rest of South America Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 233. Rest of South America Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 234. Asia Pacific Bio-pharmaceuticals, by Country USD Million (2019-2024)
  • Table 235. Asia Pacific Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 236. Asia Pacific Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 237. Asia Pacific Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 238. Asia Pacific Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 239. Asia Pacific Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 240. China Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 241. China Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 242. China Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 243. China Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 244. China Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 245. Japan Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 246. Japan Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 247. Japan Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 248. Japan Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 249. Japan Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 250. India Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 251. India Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 252. India Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 253. India Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 254. India Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 255. South Korea Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 256. South Korea Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 257. South Korea Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 258. South Korea Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 259. South Korea Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 260. Taiwan Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 261. Taiwan Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 262. Taiwan Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 263. Taiwan Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 264. Taiwan Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 265. Australia Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 266. Australia Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 267. Australia Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 268. Australia Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 269. Australia Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 270. Rest of Asia-Pacific Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 271. Rest of Asia-Pacific Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 272. Rest of Asia-Pacific Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 273. Rest of Asia-Pacific Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 274. Rest of Asia-Pacific Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 275. Europe Bio-pharmaceuticals, by Country USD Million (2019-2024)
  • Table 276. Europe Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 277. Europe Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 278. Europe Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 279. Europe Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 280. Europe Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 281. Germany Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 282. Germany Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 283. Germany Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 284. Germany Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 285. Germany Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 286. France Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 287. France Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 288. France Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 289. France Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 290. France Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 291. Italy Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 292. Italy Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 293. Italy Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 294. Italy Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 295. Italy Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 296. United Kingdom Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 297. United Kingdom Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 298. United Kingdom Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 299. United Kingdom Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 300. United Kingdom Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 301. Netherlands Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 302. Netherlands Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 303. Netherlands Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 304. Netherlands Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 305. Netherlands Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 306. Rest of Europe Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 307. Rest of Europe Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 308. Rest of Europe Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 309. Rest of Europe Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 310. Rest of Europe Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 311. MEA Bio-pharmaceuticals, by Country USD Million (2019-2024)
  • Table 312. MEA Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 313. MEA Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 314. MEA Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 315. MEA Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 316. MEA Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 317. Middle East Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 318. Middle East Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 319. Middle East Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 320. Middle East Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 321. Middle East Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 322. Africa Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 323. Africa Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 324. Africa Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 325. Africa Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 326. Africa Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 327. North America Bio-pharmaceuticals, by Country USD Million (2019-2024)
  • Table 328. North America Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 329. North America Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 330. North America Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 331. North America Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 332. North America Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 333. United States Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 334. United States Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 335. United States Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 336. United States Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 337. United States Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 338. Canada Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 339. Canada Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 340. Canada Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 341. Canada Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 342. Canada Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 343. Mexico Bio-pharmaceuticals, by Type USD Million (2019-2024)
  • Table 344. Mexico Bio-pharmaceuticals, by Application USD Million (2019-2024)
  • Table 345. Mexico Bio-pharmaceuticals, by End Users USD Million (2019-2024)
  • Table 346. Mexico Bio-pharmaceuticals, by Technology USD Million (2019-2024)
  • Table 347. Mexico Bio-pharmaceuticals, by Sales Channel USD Million (2019-2024)
  • Table 348. Research Programs/Design for This Report
  • Table 349. Key Data Information from Secondary Sources
  • Table 350. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bio-pharmaceuticals: by Type USD Million (2013-2018)
  • Figure 5. Global Bio-pharmaceuticals: by Application USD Million (2013-2018)
  • Figure 6. Global Bio-pharmaceuticals: by End Users USD Million (2013-2018)
  • Figure 7. Global Bio-pharmaceuticals: by Technology USD Million (2013-2018)
  • Figure 8. Global Bio-pharmaceuticals: by Sales Channel USD Million (2013-2018)
  • Figure 9. South America Bio-pharmaceuticals Share (%), by Country
  • Figure 10. Asia Pacific Bio-pharmaceuticals Share (%), by Country
  • Figure 11. Europe Bio-pharmaceuticals Share (%), by Country
  • Figure 12. MEA Bio-pharmaceuticals Share (%), by Country
  • Figure 13. North America Bio-pharmaceuticals Share (%), by Country
  • Figure 14. Global Bio-pharmaceuticals share by Players 2018 (%)
  • Figure 15. Global Bio-pharmaceuticals share by Players (Top 3) 2018(%)
  • Figure 16. Global Bio-pharmaceuticals share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2018
  • Figure 20. F. Hoffmann-La Roche AG Revenue, Net Income and Gross profit
  • Figure 21. F. Hoffmann-La Roche AG Revenue: by Geography 2018
  • Figure 22. AbbVie(United States) Revenue, Net Income and Gross profit
  • Figure 23. AbbVie(United States) Revenue: by Geography 2018
  • Figure 24. Johnson& Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Johnson& Johnson (United States) Revenue: by Geography 2018
  • Figure 26. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 27. Sanofi (France) Revenue: by Geography 2018
  • Figure 28. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. AstraZeneca (United Kingdom) Revenue: by Geography 2018
  • Figure 30. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 32. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 33. Novo Nordisk (Denmark) Revenue: by Geography 2018
  • Figure 34. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 36. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 37. Eli Lilly and Company (United States) Revenue: by Geography 2018
  • Figure 38. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 39. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2018
  • Figure 40. Cadila Healthcare Limited (Zydus Cadila) (India) Revenue, Net Income and Gross profit
  • Figure 41. Cadila Healthcare Limited (Zydus Cadila) (India) Revenue: by Geography 2018
  • Figure 42. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 43. Amgen (United States) Revenue: by Geography 2018
  • Figure 44. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 45. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 46. Biocon Ltd (India) Revenue, Net Income and Gross profit
  • Figure 47. Biocon Ltd (India) Revenue: by Geography 2018
  • Figure 48. Global Bio-pharmaceuticals: by Type USD Million (2019-2024)
  • Figure 49. Global Bio-pharmaceuticals: by Application USD Million (2019-2024)
  • Figure 50. Global Bio-pharmaceuticals: by End Users USD Million (2019-2024)
  • Figure 51. Global Bio-pharmaceuticals: by Technology USD Million (2019-2024)
  • Figure 52. Global Bio-pharmaceuticals: by Sales Channel USD Million (2019-2024)
  • Figure 53. South America Bio-pharmaceuticals Share (%), by Country
  • Figure 54. Asia Pacific Bio-pharmaceuticals Share (%), by Country
  • Figure 55. Europe Bio-pharmaceuticals Share (%), by Country
  • Figure 56. MEA Bio-pharmaceuticals Share (%), by Country
  • Figure 57. North America Bio-pharmaceuticals Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Pfizer (United States)
  • F. Hoffmann-La Roche AG
  • AbbVie(United States)
  • Johnson& Johnson (United States)
  • Sanofi (France)
  • AstraZeneca (United Kingdom)
  • Novartis (Switzerland)
  • Novo Nordisk (Denmark)
  • Merck & Co., Inc. (United States)
  • Eli Lilly and Company (United States)
  • Bristol-Myers Squibb Company (United States)
  • Cadila Healthcare Limited (Zydus Cadila) (India)
  • Amgen (United States)
  • Abbott Laboratories (United States)
  • Biocon Ltd (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation